Suppr超能文献

钙通道阻滞剂AQA - 39的间接刺激作用

Indirect stimulatory action of the calcium channel blocker AQA-39.

作者信息

Urthaler F, Walker A A

出版信息

J Pharmacol Exp Ther. 1984 Aug;230(2):336-40.

PMID:6747839
Abstract

AQA-39 is a new bradycardia-inducing drug chemically related to verapamil that reduces potassium conductance and blocks calcium channels. In canine ventricular trabeculae studied at 25 degrees C and at a pacing rate of 12 stimuli per minute. AQA-39, in concentrations of 1 and 2 X 10(-5) M, had a significant positive (and only positive) inotropic effect. Propranolol significantly diminished this positive inotropic action of AQA-39. After catecholamine depletion with reserpine, AQA-39 still elicited a significant increase in contractility but the magnitude of the increment in contractile performance was considerably less than the one observed when normal muscles were exposed to AQA-39. AQA-39 had no significant inotropic action on reserpinized and atropinized muscles. From these results we can conclude that AQA-39 is not a beta adrenoceptor agonist although adrenergic influences via neuronal norepinephrine release are mediating part of the inotropic effect of the drug. Furthermore, at this low rate of stimulation and at the concentrations used, AQA-39 has no direct inotropic action of its own but part of its indirect stimulatory action is mediated through an antimuscarinic effect.

摘要

AQA - 39是一种新型的致心动过缓药物,其化学结构与维拉帕米相关,可降低钾离子电导并阻断钙通道。在25摄氏度、每分钟12次刺激的起搏频率下对犬心室小梁进行研究。浓度为1×10⁻⁵M和2×10⁻⁵M的AQA - 39具有显著的正性(且仅为正性)肌力作用。普萘洛尔可显著减弱AQA - 39的这种正性肌力作用。在用利血平使儿茶酚胺耗竭后,AQA - 39仍能引起收缩力显著增加,但收缩性能增加的幅度明显小于正常肌肉暴露于AQA - 39时所观察到的幅度。AQA - 39对利血平化和阿托品化的肌肉无显著的肌力作用。从这些结果我们可以得出结论,AQA - 39不是β肾上腺素能受体激动剂,尽管通过神经元去甲肾上腺素释放的肾上腺素能影响介导了该药物部分的肌力作用。此外,在这种低刺激频率和所用浓度下,AQA - 39自身没有直接的肌力作用,但其部分间接刺激作用是通过抗毒蕈碱效应介导的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验